ResMed Stock Price, News & Analysis (NYSE:RMD)

$87.51 -1.17 (-1.32 %)
(As of 01/23/2018 02:59 PM ET)
Previous Close$88.68
Today's Range$87.10 - $88.65
52-Week Range$62.64 - $89.72
Volume1.12 million shs
Average Volume561,321 shs
Market Capitalization$14.35 billion
P/E Ratio35.43
Dividend Yield1.58%

About ResMed (NYSE:RMD)

ResMed logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorAdvanced Medical Equipment & Technology - NEC


Debt-to-Equity Ratio0.50%
Current Ratio4.72%
Quick Ratio3.86%


Trailing P/E Ratio35.4291497975709
Forward P/E Ratio28.79
P/E Growth2.24

Sales & Book Value

Annual Sales$2.07 billion
Price / Sales6.01
Cash Flow$3.57 per share
Price / Cash24.50
Book Value$13.82 per share
Price / Book6.33


Trailing EPS$2.47
Net Income$342.28 million
Net Margins16.58%
Return on Equity21.53%
Return on Assets11.90%


Outstanding Shares141,900,000

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Monday, January 22nd. Shareholders of record on Thursday, February 8th will be given a dividend of $0.35 per share on Thursday, March 15th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.60%. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Monday, January, 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.78 by $0.22. The medical equipment provider had revenue of $601.27 million for the quarter, compared to analyst estimates of $583.77 million. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The business's quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 EPS. View ResMed's Earnings History.

Where is ResMed's stock going? Where will ResMed's stock price be in 2018?

12 brokerages have issued twelve-month price targets for ResMed's stock. Their forecasts range from $55.00 to $90.00. On average, they expect ResMed's share price to reach $67.17 in the next year. View Analyst Ratings for ResMed.

What are Wall Street analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

  • 1. According to Zacks Investment Research, "Over the recent past, ResMed has been observed to achieve strong global revenue growth led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry. However, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns." (1/19/2018)
  • 2. Needham & Company LLC analysts commented, "RMD’s revenue beat consensus and its EPS met consensus in F1Q18. Organic revenue growth improved to 10% in F1Q18 from 8% in F4Q17 as RMD saw both stronger mask and flow generator growth. RMD’s gross margin met our estimate but was offset by higher than expected SG&A and this caused RMD’s operating margin to miss our estimate. While RMD’s revenue growth was very strong, its EPS growth once again lagged which is consistent with RMD’s performance in recent years. We maintain our Underperform rating since we believe that RMD’s longer-run EPS growth is lower than its large-cap peers (despite its higher revenue growth) and its multiple is at a premium (CY17E P/E of 27.1x vs. large-cap med tech peers at 25.5x)." (10/27/2017)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:

  • Peter C. Farrell Ph.D., Non-Executive Chairman of the Board, Founder (Age 75)
  • Rob Douglas, President, Chief Operating Officer (Age 57)
  • Michael Farrell, Chief Executive Officer, Director (Age 45)
  • Brett A. Sandercock, Chief Financial Officer (Age 50)
  • Jim Hollingshead Ph.D., President – Sleep Business (Age 54)
  • Richard McHale, President – Respiratory Care (Age 53)
  • Raj Sodhi, President – Software as a Service (SaaS) Business and Chief Technology Officer (Age 44)
  • David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary (Age 57)
  • Ronald R. Taylor, Lead Independent Director (Age 69)
  • Karen Drexler, Director (Age 56)

Who owns ResMed stock?

ResMed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.49%), Capital Investment Services of America Inc. (0.13%), National Pension Service (0.12%), Professional Advisory Services Inc. (0.10%), Bank of Montreal Can (0.10%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Who sold ResMed stock? Who is selling ResMed stock?

ResMed's stock was sold by a variety of institutional investors in the last quarter, including Professional Advisory Services Inc., Gateway Investment Advisers LLC, Capital Investment Services of America Inc., Exxonmobil Investment Management Inc. TX, Tandem Investment Advisors Inc., Chevy Chase Trust Holdings Inc., Strs Ohio and Texas Permanent School Fund. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell and Richard Sulpizio. View Insider Buying and Selling for ResMed.

Who bought ResMed stock? Who is buying ResMed stock?

ResMed's stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Bank of Montreal Can, State of Alaska Department of Revenue, National Pension Service, Coastline Trust Co, West Coast Financial LLC and LaFleur & Godfrey LLC. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy ResMed stock?

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of ResMed stock can currently be purchased for approximately $87.51.

How big of a company is ResMed?

ResMed has a market capitalization of $14.35 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.47 on an earnings per share basis. ResMed employs 6,080 workers across the globe.

How can I contact ResMed?

ResMed's mailing address is 9001 Spectrum Center Blvd, SAN DIEGO, CA 92123-1438, United States. The medical equipment provider can be reached via phone at +1-858-7462400 or via email at [email protected]

MarketBeat Community Rating for ResMed (RMD)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  438 (Vote Underperform)
Total Votes:  638
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ResMed (NYSE:RMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.001.911.901.80
Ratings Breakdown: 3 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $67.17$65.83$64.80$61.29
Price Target Upside: 23.25% downside23.84% downside15.35% downside9.78% downside

ResMed (NYSE:RMD) Consensus Price Target History

Price Target History for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2018Northland SecuritiesUpgradeUnder Perform -> Market PerformHighView Rating Details
1/23/2018MacquarieDowngradeNeutral -> UnderperformHighView Rating Details
1/23/2018BMO Capital MarketsBoost Price TargetMarket Perform$90.00HighView Rating Details
1/23/2018Needham & Company LLCUpgradeUnderperform -> HoldHighView Rating Details
10/30/2017JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 -> $73.00N/AView Rating Details
10/27/2017BarclaysBoost Price TargetUnderweight$68.00 -> $70.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingSell$56.00N/AView Rating Details
8/8/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
8/2/2017CitigroupUpgradeNeutral -> BuyHighView Rating Details
8/2/2017Bank of AmericaDowngradeBuy -> NeutralHighView Rating Details
4/13/2017William BlairReiterated RatingOutperformLowView Rating Details
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/AView Rating Details
4/27/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$65.00 -> $57.00N/AView Rating Details
(Data available from 1/23/2016 forward)


ResMed (NYSE:RMD) Earnings History and Estimates Chart

Earnings by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/22/2018Q2 2018$0.78$1.00$583.77 million$601.27 millionViewListenView Earnings Details
10/26/2017Q1 2018$0.66$0.66$506.08 million$523.66 millionViewN/AView Earnings Details
8/1/2017Q4 2017$0.75$0.77$557.68 million$556.69 millionViewListenView Earnings Details
4/27/2017Q3 2017$0.70$0.71$525.84 million$514.20 millionViewN/AView Earnings Details
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
10/28/2010Q1 2011$0.32$0.36ViewN/AView Earnings Details
8/5/2010Q4 2010$0.33$0.34ViewN/AView Earnings Details
4/29/2010Q3 2010$0.29$0.32ViewN/AView Earnings Details
2/4/2010Q2 2010$0.28$0.31ViewN/AView Earnings Details
11/5/2009Q1 2010$0.25$0.29ViewN/AView Earnings Details
8/6/2009Q4 2009$0.27$0.31ViewN/AView Earnings Details
5/7/2009Q3 2009$0.23$0.25ViewN/AView Earnings Details
2/5/2009Q2 2009$0.21$0.22ViewN/AView Earnings Details
11/6/2008Q1 2009$0.19$0.18ViewN/AView Earnings Details
8/5/2008Q4 2008$0.19$0.19ViewN/AView Earnings Details
5/1/2008Q3 2008$0.20$0.19ViewN/AView Earnings Details
2/7/2008Q2 2008$0.20$0.18ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


ResMed (NYSE:RMD) Earnings Estimates

2018 EPS Consensus Estimate: $2.94
2019 EPS Consensus Estimate: $2.57
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.63$0.65$0.64
Q2 20182$0.74$0.77$0.76
Q3 20182$0.72$0.75$0.74
Q4 20182$0.77$0.84$0.81
Q1 20191$0.73$0.73$0.73
Q2 20191$0.84$0.84$0.84
Q3 20191$0.81$0.81$0.81
Q4 20191$0.19$0.19$0.19
(Earnings estimates data provided by Zacks Investment Research)


ResMed (NYSE:RMD) Dividend Information

Next Dividend:3/15/2018
Annual Dividend:$1.40
Dividend Yield:1.60%
Dividend Growth:8.70% (3 Year Average)
Payout Ratio:56.68% (Trailing 12 Months of Earnings)
46.05% (Based on This Year's Estimates)
41.18% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ResMed (NYSE RMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.77%
Institutional Ownership Percentage: 61.85%
Insider Trades by Quarter for ResMed (NYSE:RMD)
Institutional Ownership by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Brett SandercockCFOSell1,250$84.99$106,237.5078,322View SEC Filing  
1/2/2018James HollingsheadInsiderSell600$84.96$50,976.0062,602View SEC Filing  
12/4/2017David PendarvisInsiderSell2,804$84.17$236,012.6897,257View SEC Filing  
12/1/2017Brett SandercockCFOSell1,250$85.36$106,700.0079,572View SEC Filing  
11/20/2017James HollingsheadInsiderSell7,019$84.16$590,719.0466,409View SEC Filing  
11/9/2017Peter C FarrellDirectorSell118,392$82.70$9,791,018.40306,615View SEC Filing  
11/6/2017Peter C FarrellDirectorSell20,000$83.53$1,670,600.00314,800View SEC Filing  
11/3/2017David PendarvisInsiderSell6,364$82.20$523,120.80View SEC Filing  
11/1/2017Brett SandercockCFOSell1,250$84.50$105,625.0071,772View SEC Filing  
10/4/2017Peter C FarrellDirectorSell20,000$77.01$1,540,200.00View SEC Filing  
10/3/2017David PendarvisInsiderSell6,364$76.94$489,646.16View SEC Filing  
10/2/2017Brett SandercockCFOSell1,250$77.05$96,312.5064,691View SEC Filing  
9/5/2017David PendarvisInsiderSell6,364$77.21$491,364.4493,172View SEC Filing  
9/5/2017Peter C FarrellDirectorSell20,000$76.74$1,534,800.00314,800View SEC Filing  
9/1/2017Brett SandercockCFOSell1,250$77.56$96,950.0065,941View SEC Filing  
8/9/2017Richard SulpizioDirectorSell24,390$73.85$1,801,201.5028,819View SEC Filing  
8/4/2017Peter C FarrellDirectorSell20,000$75.15$1,503,000.00321,557View SEC Filing  
8/3/2017David PendarvisInsiderSell6,364$72.10$458,844.4084,476View SEC Filing  
8/1/2017Brett SandercockCFOSell1,250$77.49$96,862.5059,258View SEC Filing  
7/14/2017James HollingsheadInsiderSell7,140$77.43$552,850.20View SEC Filing  
7/5/2017Peter C FarrellDirectorSell20,000$76.50$1,530,000.00321,557View SEC Filing  
7/3/2017Brett SandercockCFOSell1,250$77.44$96,800.0060,508View SEC Filing  
7/3/2017David PendarvisInsiderSell6,364$77.36$492,319.0484,476View SEC Filing  
6/29/2017Jr. Gregor K EmmertInsiderBuy282,000$0.07$19,740.00
6/28/2017Jr. Gregor K EmmertInsiderBuy424,000$0.06$25,440.00
6/22/2017Richard SulpizioDirectorSell65,887$77.82$5,127,326.344,429View SEC Filing  
6/15/2017Gary W PaceDirectorSell24,390$76.00$1,853,640.0099,317View SEC Filing  
6/5/2017David PendarvisInsiderSell6,365$72.62$462,226.3084,477View SEC Filing  
6/5/2017Peter C FarrellDirectorSell20,000$72.65$1,453,000.00321,557View SEC Filing  
6/1/2017Brett SandercockCFOSell1,250$71.02$88,775.00View SEC Filing  
5/4/2017Peter C FarrellDirectorSell20,000$68.75$1,375,000.00321,557View SEC Filing  
5/3/2017David PendarvisInsiderSell6,365$69.55$442,685.7584,261View SEC Filing  
5/1/2017Brett SandercockCFOSell1,250$68.60$85,750.0062,783View SEC Filing  
4/17/2017James HollingsheadInsiderSell7,139$68.37$488,093.4344,934View SEC Filing  
4/4/2017Peter C FarrellDirectorSell20,000$70.67$1,413,400.00321,557View SEC Filing  
4/3/2017Brett SandercockCFOSell1,250$71.65$89,562.5064,033View SEC Filing  
4/3/2017David PendarvisInsiderSell6,365$71.59$455,670.3584,261View SEC Filing  
3/1/2017Brett SandercockCFOSell1,250$72.48$90,600.0065,283View SEC Filing  
2/24/2017John P WarehamDirectorSell28,403$71.77$2,038,483.3141,403View SEC Filing  
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00145,610View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00321,557View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.4084,261View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.9646,754View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00321,557View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.7584,261View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.0084,261View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00372,407View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00367,978View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.5745,513View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.5252,744View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75203,781View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00364,063View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.0087,061View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.0087,061View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00367,978View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00129,158View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.3116,729View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.5016,729View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00101,887View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.8037,390View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00367,978View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.0080,512View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25154,814View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.0640,669View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00367,978View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.0080,512View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.2043,422View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25154,814View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00367,978View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.0080,512View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00154,723View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00367,978View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.0080,287View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50154,723View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.0080,287View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00367,978View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.0047,569View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75150,852View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00129,158View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00367,978View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.0080,287View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.7676,300View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00132,136View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00101,887View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80347,978View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00144,878View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00347,978View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.0074,287View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.04$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25144,878View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.0074,287View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00347,978View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.8931,304View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.0052,069View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.0074,287View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.4131,304View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.06$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.06$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00109,610View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25144,878View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.2413,684View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.8068,391View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.0083,214View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25172,370View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.0077,180View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.2968,179View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17289,826View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.8567,680View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75172,370View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.0077,180View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.3275,316View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00289,826View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.0083,214View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.8061,527View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00106,655View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.0013,000View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.0066,423View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.0071,423View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00304,990View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.0068,956View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00304,990View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.0068,956View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.0084,215View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00489,876View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00100,572View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.0094,902View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.0026,285View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.5218,588View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00123,892View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00880,000View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00109,012View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.0090,000View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


ResMed (NYSE RMD) News Headlines

33 Stocks Moving In Tuesdays Mid-Day Session33 Stocks Moving In Tuesday's Mid-Day Session - January 23 at 2:35 PM
Heres Why ResMed Inc. Is Soaring TodayHere's Why ResMed Inc. Is Soaring Today - January 23 at 1:26 PM
ResMed (RMD) Lowered to "Underperform" at MacquarieResMed (RMD) Lowered to "Underperform" at Macquarie - January 23 at 9:08 AM
Resmed Inc Earnings Rise 39% In Q2 - - NasdaqResmed Inc Earnings Rise 39% In Q2 - - Nasdaq - January 23 at 5:11 AM
Earnings Reaction History: ResMed Inc., 100.0% Follow-Through Indicator, 6.3% Sensitive - NasdaqEarnings Reaction History: ResMed Inc., 100.0% Follow-Through Indicator, 6.3% Sensitive - Nasdaq - January 23 at 5:11 AM
ResMed Inc. (RMD) Q2 2018 Earnings Conference Call TranscriptResMed Inc. (RMD) Q2 2018 Earnings Conference Call Transcript - January 23 at 5:11 AM
ResMed Inc. Plans Quarterly Dividend of $0.35 (RMD)ResMed Inc. Plans Quarterly Dividend of $0.35 (RMD) - January 22 at 6:31 PM
ResMed (RMD) Announces  Earnings ResultsResMed (RMD) Announces Earnings Results - January 22 at 5:02 PM
Are ResMed Inc’s (NYSE:RMD) Interest Costs Too High?Are ResMed Inc’s (NYSE:RMD) Interest Costs Too High? - January 22 at 1:07 PM
ResMed (RMD) Downgraded by Zacks Investment ResearchResMed (RMD) Downgraded by Zacks Investment Research - January 19 at 1:54 PM
ResMed (RMD) Rating Increased to Buy at Zacks Investment ResearchResMed (RMD) Rating Increased to Buy at Zacks Investment Research - January 18 at 3:16 PM
Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings? - January 17 at 11:33 AM
ResMed Inc. (RMD) Receives Consensus Rating of "Hold" from AnalystsResMed Inc. (RMD) Receives Consensus Rating of "Hold" from Analysts - January 15 at 3:40 PM
ResMed (RMD) Set to Announce Quarterly Earnings on MondayResMed (RMD) Set to Announce Quarterly Earnings on Monday - January 15 at 3:02 AM
$577.00 Million in Sales Expected for ResMed Inc. (RMD) This Quarter$577.00 Million in Sales Expected for ResMed Inc. (RMD) This Quarter - January 13 at 6:36 AM
ResMed Inc. (RMD) Expected to Post Earnings of $0.78 Per ShareResMed Inc. (RMD) Expected to Post Earnings of $0.78 Per Share - January 11 at 5:24 PM
ResMed (RMD) Downgraded to "Hold" at Zacks Investment ResearchResMed (RMD) Downgraded to "Hold" at Zacks Investment Research - January 11 at 4:08 PM
Stock Review for Medical Equipments Investors -- Boston Scientific, Wright Medical, Hologic, and ResMed - PR Newswire (press release)Stock Review for Medical Equipment's Investors -- Boston Scientific, Wright Medical, Hologic, and ResMed - PR Newswire (press release) - January 8 at 3:30 PM
Interesting RMD Put And Call Options For February 16thInteresting RMD Put And Call Options For February 16th - January 5 at 3:26 PM
Zacks Investment Research Upgrades ResMed (RMD) to HoldZacks Investment Research Upgrades ResMed (RMD) to Hold - January 5 at 2:02 PM
Comparing Accelerate Diagnostics (AXDX) & ResMed (RMD)Comparing Accelerate Diagnostics (AXDX) & ResMed (RMD) - January 5 at 9:32 AM
James Hollingshead Sells 600 Shares of ResMed Inc. (RMD) StockJames Hollingshead Sells 600 Shares of ResMed Inc. (RMD) Stock - January 4 at 12:38 PM
ResMed Inc. (RMD) CFO Sells $106,237.50 in StockResMed Inc. (RMD) CFO Sells $106,237.50 in Stock - January 4 at 12:38 PM
ResMed to Announce Second Quarter Fiscal Year 2018 ResultsResMed to Announce Second Quarter Fiscal Year 2018 Results - January 4 at 8:38 AM
Zacks: Brokerages Anticipate ResMed Inc. (RMD) Will Post Quarterly Sales of $577.00 MillionZacks: Brokerages Anticipate ResMed Inc. (RMD) Will Post Quarterly Sales of $577.00 Million - December 28 at 11:32 PM
ResMed (RMD) Downgraded to "Sell" at Zacks Investment ResearchResMed (RMD) Downgraded to "Sell" at Zacks Investment Research - December 26 at 3:38 PM
ResMed Inc. (RMD) Receives Average Rating of "Hold" from AnalystsResMed Inc. (RMD) Receives Average Rating of "Hold" from Analysts - December 21 at 6:06 PM
Head to Head Review: ResMed (RMD) versus Hologic (HOLX)Head to Head Review: ResMed (RMD) versus Hologic (HOLX) - December 19 at 11:24 AM
Derma Sciences (DSCI) & ResMed (RMD) Head to Head SurveyDerma Sciences (DSCI) & ResMed (RMD) Head to Head Survey - December 17 at 1:28 AM
Analyzing Pacific Biosciences of California (PACB) & ResMed (RMD)Analyzing Pacific Biosciences of California (PACB) & ResMed (RMD) - December 13 at 9:38 PM
BMO Capital Markets Raises ResMed (RMD) Price Target to $82.00BMO Capital Markets Raises ResMed (RMD) Price Target to $82.00 - December 12 at 11:28 AM
Why the ResMed Inc. (CHESS) share price is falling todayWhy the ResMed Inc. (CHESS) share price is falling today - December 12 at 8:43 AM
 Brokerages Expect ResMed Inc. (RMD) to Post $0.76 EPS Brokerages Expect ResMed Inc. (RMD) to Post $0.76 EPS - December 8 at 9:36 AM
ResMed Inc. (RMD) Insider Sells $236,012.68 in StockResMed Inc. (RMD) Insider Sells $236,012.68 in Stock - December 5 at 6:48 PM
ResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 SharesResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 Shares - December 4 at 7:00 PM
ResMed (RMD) Rides on Innovation Amid Reimbursement Woes - NasdaqResMed (RMD) Rides on Innovation Amid Reimbursement Woes - Nasdaq - December 3 at 8:01 AM
Morgans unveils its “high conviction” stock picks for 2018Morgans unveils its “high conviction” stock picks for 2018 - December 1 at 10:49 AM
Detailed Research: Economic Perspectives on Cimarex Energy, Las Vegas Sands, Echelon, ResMed, Qorvo, and Integrated Device Technology — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Cimarex Energy, Las Vegas Sands, Echelon, ResMed, Qorvo, and Integrated Device Technology — What Drives Growth in Today's Competitive Landscape - December 1 at 10:49 AM
ResMed (RMD) Rides on Innovation Amid Reimbursement WoesResMed (RMD) Rides on Innovation Amid Reimbursement Woes - December 1 at 10:49 AM
Free Post Earnings Research Report: ResMed’s Revenue and EPS Jumped 13% Y-O-YFree Post Earnings Research Report: ResMed’s Revenue and EPS Jumped 13% Y-O-Y - November 30 at 8:41 AM
Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report?Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report? - November 29 at 8:39 AM
ETFs with exposure to ResMed, Inc. : November 27, 2017ETFs with exposure to ResMed, Inc. : November 27, 2017 - November 27 at 4:22 PM
ResMed Inc. (RMD) Receives Average Rating of "Hold" from BrokeragesResMed Inc. (RMD) Receives Average Rating of "Hold" from Brokerages - November 26 at 6:14 PM
James Hollingshead Sells 7,019 Shares of ResMed Inc. (RMD) StockJames Hollingshead Sells 7,019 Shares of ResMed Inc. (RMD) Stock - November 22 at 1:40 PM
Zacks: Analysts Anticipate ResMed Inc. (RMD) to Post $0.76 EPSZacks: Analysts Anticipate ResMed Inc. (RMD) to Post $0.76 EPS - November 20 at 1:38 PM
ResMed Elects Karen Drexler to Its Board of DirectorsResMed Elects Karen Drexler to Its Board of Directors - November 18 at 11:26 AM
Statement by ResMed on United Kingdom Case with Fisher & PaykelStatement by ResMed on United Kingdom Case with Fisher & Paykel - November 14 at 7:23 AM
ETFs with exposure to ResMed, Inc. : November 13, 2017ETFs with exposure to ResMed, Inc. : November 13, 2017 - November 14 at 7:23 AM
ResMed Inc. (RMD) Director Peter C. Farrell Sells 118,392 SharesResMed Inc. (RMD) Director Peter C. Farrell Sells 118,392 Shares - November 13 at 6:04 PM
SleepScore Labs Launches the Worlds Most Advanced Sleep Improvement SystemSleepScore Labs Launches the World's Most Advanced Sleep Improvement System - November 12 at 12:21 PM

SEC Filings

ResMed (NYSE:RMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


ResMed (NYSE:RMD) Income Statement, Balance Sheet and Cash Flow Statement


ResMed (NYSE RMD) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.